WO2012142615A2 - Auranofine et analogues d'auranofine utiles pour traiter une maladie proliférative et des troubles prolifératifs - Google Patents

Auranofine et analogues d'auranofine utiles pour traiter une maladie proliférative et des troubles prolifératifs Download PDF

Info

Publication number
WO2012142615A2
WO2012142615A2 PCT/US2012/033837 US2012033837W WO2012142615A2 WO 2012142615 A2 WO2012142615 A2 WO 2012142615A2 US 2012033837 W US2012033837 W US 2012033837W WO 2012142615 A2 WO2012142615 A2 WO 2012142615A2
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
compounds
stat3
auranofin
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/033837
Other languages
English (en)
Other versions
WO2012142615A3 (fr
Inventor
Waldemar Priebe
Takayuki Kato
Izabela Fokt
Charles Conrad
Timothy Madden
Stanislaw Skora
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of WO2012142615A2 publication Critical patent/WO2012142615A2/fr
Publication of WO2012142615A3 publication Critical patent/WO2012142615A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12

Definitions

  • the present disclosure is directed to compounds that modulate p-STAT3, their synthesis, and their application as a pharmaceutical for the treatment of disease.
  • Persistently activated STATS plays a central role in cellular transformation. It induces target genes which promote tumor cell proliferation, survival and invasion, regulates the communication between tumor ceils and normal cells and thus contributes to the evasion of tumors.
  • STAT3 has been shown to be constitutively activated in cancer including, but not limited to, cancers of the brain, head, neck, breast, prostate, lung, ovary, pancreas, leukemia, multiple myeloma, and lymphoma. See e.g., Song, J.I., et al., STA T Signaling in Head and Neck Cancer, Oncogene, 19, 2489-2495 (2000); Garcia, R., et al, Constitutive Activation of STATS in Fibroblasts Transformed By Diverse Oncoproteins and in Breast Carcinoma Cells, Cell Growth Duff, 812, 1267-76 (1997); Schaefer, L.
  • Anti-cancer drugs under investigation include small molecular weight compounds, metal complexes, oligonucleotides, cell permeable peptides and peptidomimetics. Indeed, the medicinal use of metal-containing compounds has become increasingly of interest. For example, compounds that contain platinum has become one of the most widely used groups of anti-cancer drugs and includes drugs such as cisplatin, carbopJatin and oxaliptatin. Recently, ependymoma, a aggressive form of brain cancer has been shown to partially respond to platinum compounds,
  • STAT3 are provided together methods of synthesizing and methods of using the compounds. Also provided are methods of treating p-STAT3 diseases and disorders in a patient in need thereof by administering a therapeutically effective amount of one or more of these compounds, alone or in combination with another drug therapy.
  • the compounds and pharmaceutical compositions disclosed are useful to treat proliferative diseases and disorders including, but not limited to, cancer of the brain, head, neck, breast, prostate, lung, ovary, pancreas, leukemia, multiple myeloma, lymphoma and others.
  • Rl, R2, R3, R4, R5 are each optionally substituted with H, OH, O-acyl, O-aikyi, NH 2 ,
  • R6 is optionally substituted with a lower alkyl
  • compositions comprising one or more of the compounds presented herein together with a pharmaceutically acceptable carrier as well as methods of making and using the compounds and compositions, alone or in combination with another drug product.
  • Methods for treating a proliferative disease or disorder in a patient in need of such treatment are further provided.
  • the compounds of Formula I possess useful STAT3 inhibiting or modulating activity and may be used in the treatment or prophylaxis of a disease or condition in which STAT3 plays an active role.
  • Methods of treating disease comprise the step of administering to said patient a therapeutically effective amount of a compounds or compositions described herein.
  • the compounds disclosed herein are suitable for use in the manufacture of a medicament for the treatment of a diseases or condition ameliorated by the inhibition of STAT3.
  • Figures 1A, IB, and 1C provide our data that shows auranofm inhibits 58-10F ependymoma cell line growth and blocks expression of pSTAT3 in ependymoma 58-lOF.
  • Figures 2A, 2B, 2C, and 2D provide our data that shows auranoim inhibits BT-58 ependymoma cell line growth and blocks expression of constitutively activated STATS.
  • Figures 3A, B and C provide our data that shows auranofm inhibits BT-58 ependymoma eel! line growth and blocks IL-6 stimulated p-ST ATS.
  • Figure 4 teaches that ependymoma tumor eel! lines (58-l OF, BT-58) are more sensitive to auranofm than glioma tumor cells (U87).
  • Figure 5 shows that ependymoma tumor cell lines (58-lOF, BT-58) were more sensitive to the compound of Example 3 than glioma tumor cells (U87).
  • Figure 6 shows that ependymoma tumor cell lines (58-10F, BT-58) are more sensitive to the compound of Example 6 than glioma tumor cells (U87).
  • Figure 7 shows that auranofin inhibits HH CTCL eel! growth and blocks expression of p-STAT3.
  • Figures 8A, 8B and 8C provide the survival of melanoma (WM35) cells after 24 hours, 48 hours and 72 hours of exposure to auranofin at various concentrations: 1 , 0.5, 1 , 2, 3, 4, and 10 ⁇ .
  • Figure 8B shows the relative level of pSTAT3 after 4 hours of drug exposure in different concentrations.
  • Figure 8C is a Western blot showing the concentration of pSTAT3, tSTAT3 and ⁇ Actin.
  • Figure 9 shows the effects of 1 ⁇ auranofm in combination with 10 lU/ml IFNa or 20 ng/ml IL-6 on the proliferation of CTCL HH in normoxia or hypoxia condition for 72 hours.
  • Figure 10 shows the MTS of treating CTL HH, Hut78, and MS WP1527 (0., 0.5,
  • Figure 1 1 shows the effects of Auranofm, WP1531, WP1533 on pSTAT3 expression in BT-58 for 4 h with 5 lU/ml of IFNa stimulation for 30 min in 10% serum.
  • Figure 12 shows the effects of Auranofm, WP1531, and WP1533 on the proliferation of BT-58 and 58-1 OF for 72 h (MTS).
  • Figure 13 shows the effects of WP1547 on the proliferation of BT-58, 58-10F,
  • Figure 14 shows the effects of WP1546 on the proliferation of BT-58, 58-10F
  • Gold and its compounds have been used as medicines since ancient times.
  • the application of gold compounds to medicine is often called “chrysotherapv” and "aurotherapy.”
  • Some of the gold compounds are currently approved for therapeutic use and are known for their ability to reduce inflammation and are used in rheumatoid arthritis.
  • Auranofm is an example of such drug.
  • the chemical structure of auranofm is:
  • Ac is acetyl or optionally substituted COCH 3 group; and R can be optionally substituted acyl (valproates and butyrates) or H.
  • the term "optionally substituted” means the anteceding group may be substituted or unsubstituted.
  • the substituents of an "optionally substituted” group may include, without limitation, one or more substituents independently selected from the following groups or a particular designated set of groups, alone or in combination: lower alkyl, lower alkenyl, lower aikynyl, lower alkaiioyl, lower heteroalkyl, lower heterocycloalkyl, lower haloalkyl, lower haloalkenyl, lower haloalkynyl, lower perhaloalkyl, lower perhaioalkoxy, lower cvcloalkyl, phenyl, aryl, aryloxy, lower alkoxy, lower haloalkoxy, oxo, lower acyloxy, carbonyi, carboxyl, lower alkylcarbonyl, low r er carboxyester, lower carboxamido, cyano, hydrogen,
  • Two substituents may be joined together to form a fused five-, six-, or seven-menbered carbocyciic or heterocyclic ring consisting of zero to three heteroatoms, for example forming methyl en edioxy or ethylenedioxy.
  • An optionally substituted group may be unsubstituted (e.g., -C3 ⁇ 4CH 3 ), folly substituted (e.g., -CF 2 CF 3 ), monosubstituted (e.g., -CH 2 CH 2 F) or substituted at a level anywhere in-between fully substituted and monosubstituted (e.g., -C3 ⁇ 4CF 3 ).
  • R or the term R' appearing by itself and without a number designation, unless otherwise defined, refers to a moiety selected from the group consisting of hydrogen, alkyl, acyi, cycioalkyl, heteroalkyl, aryl, heteroaryl and heterocycloalkyl, any of which may be optionally substituted.
  • aryl, heterocycle, R, etc. occur more tha one time in a formula or generic structure, its definition at each occurrence is independent of the definition at every other occurrence.
  • certain groups may be attached to a parent molecule or may occupy a position in a chain of elements from either end as written.
  • an unsymmetrical group such as -C(0)N(R)- may be attac ed to the parent moiety at either the carbon or the nitrogen.
  • Proliferative disease means and includes, but is not limited to, psoriasis, skin cancer, CNS cancer including brain cancer and cancer metastatic to CNS, ovarian cancer, head cancer, neck cancer, prostate cancer, hematological malignancies including leukemia, lymphoma and myeloma, breast cancer, skin cancer including squamous cell carcinomas, basal cell cancers, cutaneous T-cell lymphomas, primary cutaneous B cell lymphomas, Derniatofibrosarcoma protuberans, Merkel cell carcinoma, Kaposi's sarcoma, keratoacanthoma, and melanoma.
  • Additional proliferative diseases include for example, breast cancer; lung cancer, including non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC), gastrointestinal cancer, including esophageal, gastric, small bowel, large bowel, rectal and colon cancer, CNS melanoma, Leptomeningeal disease (LMD), cancer metastatic to CNS, sarcoma, such as those involving bone, cartilage, soft tissue, muscle, blood and lymph vessels, ovarian cancer; female cervical cancer, endometrial cancer, mesothelioma, renal cancer, uteran, bladder and urethral cancers.
  • NSCLC non-small cell lung cancer
  • SCLC small-cell lung cancer
  • gastrointestinal cancer including esophageal, gastric, small bowel, large bowel, rectal and colon cancer, CNS melanoma, Leptomeningeal disease (LMD), cancer metastatic to CNS, sarcoma, such as those involving bone, cartilage, soft
  • metastasis in the original organ or tissue and/or in any other location is implied alternatively or in addition, whatever the location of the tumor.
  • the proliierative disease may be refractory to one or more existing cancer treatments.
  • refractory in this context is meant that the proliferative disease does not respond to treatment.
  • the proliferative disease may be resistant at the beginning of treatment or it may become resistant during treatment.
  • the compounds described herein may be useful for the treatment of a wide variety of disorders or conditions where inhibition or modulation of the STAT3 pathway is needed.
  • the compounds decrease and can therapeutically treat proliferative disease conditions.
  • Uses for these compounds include the compounds as agents to: decrease STATS activity; STAT3 phosphorylation; and the expression of proteins controlled by transcriptional activation by activated STAT3.
  • the compounds can be specifically used as agents to decrease VEGF, MMP9, MMP2, survivin, c-Myc, MMP-1, MEK-5, c-FOS,l COX-2, Bcl-xl, MMP-10, HSP-27 and Jmjdla.
  • disorders or conditions that can be prevented or treated by compounds and methods described herein include the prevention or treatment of cancer, such as cutaneous T-cell leukemia, head and neck tumors, pancreatic cancer, bladder cancer, high grade gliomas, ependymomas, brain metastasis, melanoma, skin cancer, lung cancer, breast cancer, prostate cancer, colon cancer, leukemia, myelodysplastic syndrome (a pre-leukemia condition), and multiple myeloma.
  • metastasis of any cancer can be prevented or treated with the compounds and methods described herein.
  • the compounds can also be used to prevent or treat proliferative angiogenic conditions including telangectasia, venous angiomas, hemangioblastoma.
  • methods of preventing or treating proliferative diseases or disorders of the skin comprise the step of administrating to a patient in need thereof a therapeutically effective amount of a compound described herein.
  • CNS Central Nervous System
  • diseases and conditions such as CNS inflammatory and conditions, e.g., multiple sclerosis and progressive multifocal leukoencephalopathy,
  • the compounds described herein can be used to prevent or treat inflammatory diseases and conditions, such as osteoarthritis, rheumatoid arthritis, Crohn's disease, ulcerative colitis, and auto-immune diseases such as lupus and mixed auto-immune disease by administrating a therapeutically effective amount of the compound to a patient in need thereof.
  • inflammatory diseases and conditions such as osteoarthritis, rheumatoid arthritis, Crohn's disease, ulcerative colitis, and auto-immune diseases such as lupus and mixed auto-immune disease
  • telangectasia venous angiomas
  • hemangioblastoma hemangioblastoma
  • polycythemia vera may also be advantageously prevented or treated with the compounds described herein,
  • the compounds provided herein can affect stem cell survival and differentiation by maintaining stem cell sternness, e.g., preventing the differentiation of stem cells.
  • the compounds taught herein may also be used for the augmentation of immune response, particularly where the augmentation of the immune response leads to the expression of co- stimulatory molecules on the peripheral macrophages and tumor-infiltrating microglia. These compounds are also useful when the immune response leads to proliferation of effector T cells and/or up-regulation of several key intracellular signaling molecules that critically regulate T- cell and monocyte activation.
  • inhibitors of STATS are useful in treating a wide variety of cancers because these inhibitors provide tumor cytotoxic effects - whether acting directly or indirectly on the activation of STAT3 and/or whether the inhibitor prevents activation of STAT3, upstream or downstream in its pathway.
  • STAT3 blockade agents also referred to sometimes as a "STATS inhibitors"
  • STAT3 blockade agents have multiple mechanisms of activity and potentially conflicting effects.
  • the various targets of STAT3 blockade agents include molecules in the STATS activation pathway of both tumor cells and immune cells. As such, this effect can adversely impact the potential wide spread uses of STAT3 inhibitors.
  • tyrosine kinase receptors and non-receptor tyrosine kinases such as SRC can be activated by extrinsic pathways such as factors associated with inflammation such as UV radition or sunlight, chemical carcinogens, infection, stress and cigarette smoke, in turn, the tyrosine kinases induced by both extrinsic and instrinsic pathways phosphorylate STAT3 which in turn forms dimers that translocate to the nucleus where gene expression is directly regulated.
  • STAT3 will induce the expression of many cytokines, chemokines and other mediators such as IL-6 and cyclooxgenase 2 that are associated with cancer-promoting inflammation. Most importantly, the receptors for many of the cytokines further active STAT3.
  • Novel analogs of auranofin also referred to herein as "aurofin analogs" which can act as inhibitors of STATS are disclosed in Exampl es 1 to 8 of the present appl ication.
  • Additional inhibitors of STAT3 that may useful in connection with the methods provided herein include direct and indirect inhibitors of STATS.
  • Potential indirect inhibitors of STAT3 phosphorylation include inhibitors of upstream activators like growth factors, cytokines, src, Tyk2 and Janus kinases (this includes Jak2, Jak3, and Tyk2 inhibitors).
  • Key activators of STAT3 include IL-6, J L-10, I L-23, IL-11 and OSM.
  • Molecules upreguiated by STAT3 which may be modulated by a STAT3 inhibitor include but are not limited to BCL-X L , MYC, BIRC5, MMP9, MMP2, HIFa, ICAM1, TWIST 1 , VIM, MCLl , HSP70 and HSP90, IL-10, VEGF, FGF2 (also known as BFGF), COX2 CXCL12 (also known as SDFl), IL-11, IL-23, IL-17, and IL6.
  • Molecules dowrtregulated by STAT3 include IL-6, IL-12A (also known as P35), CD80, CD86, CXCL10 (also known as IP-10), IFN , IFNp, CCL5, NOS2, IL-8, IL- ⁇ , and CCL2 (also known as MCPl).
  • More specifically potential indirect inhibitors of STAT3 include the Jak2 inhibitors currently under clinical trials such as: INCBO 18424 by Incyte; TG101348 by TargeGen; CEP-701 (lestaurtinib) by Cephalon; AZD1480 by AstraZeneca; XL019 by Exelixis; CYT-387 by Cytopia; SGI-1252 by SuperGen; and SB1518 by S*BIO.
  • the Jak2 Inhibitors in preclinical development can also be useful as an indirect inhibitor of STAT3 and include: AG490; Tkip; Z3; TG I 01209; and C7.
  • non-specific inhibitors of Jak2 can be useful and currently including: Go6976; Erlotinib; Atiprimod; CP-690,550; AT9283; and MK- 0457.
  • the subject invention provides a pharmaceutical formulation comprising a compound or a pharmaceutically acceptable salt, ester, prodrug or solvate thereof, together with one or more pharmaceutically acceptable carriers thereof and optionally one or more other therapeutic ingredients.
  • the carrier(s) must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. Proper formulation is dependent upon the route of administration chosen. Any of the well-known techniques, carriers, and excipients may be used as suitable and as understood in the art; e.g., in Remington's Pharmaceutical Sciences.
  • compositions of the present invention may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or compression processes,
  • the formulations include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous, intraarticular, and intramedullary), intraperitoneal, transmucosal, transdermal, rectal and topical (including dermal, buccal, sublingual and intraocular) administration although the most suitable route may depend upon for example the condition and disorder of the recipient.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association a compound of the subject invention or a pharmaceutically acceptable salt, ester, prodrug or solvate thereof ("active ingredient”) with the carrier which constitutes one or more accessory ingredients.
  • active ingredient a pharmaceutically acceptable salt, ester, prodrug or solvate thereof
  • the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
  • formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.
  • the compounds of the invention may be administered orally or via injection at a dose of from 0.1 to 500 mg kg per day.
  • the dose range for adult humans is generally from 5 mg to 2 g/day.
  • Tablets or other forms of presentation provided in discrete units may conveniently contain an amount of compound of the invention which is effective at such dosage or as a multiple of the same, for instance, units containing 5 mg to 500 mg, usually around 10 mg to 200 mg.
  • the amount of active ingredient thai may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
  • the compounds of the subject invention can be administered in various modes, e.g. orally, topically, or by injection.
  • the precise amount of compound administered to a patient will be the responsibility of the attendant physician.
  • the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diets, time of administration, route of administration, rate of excretion, drag combination, the precise disorder being treated, and the severity of the indication or condition being treated.
  • the route of administration may vary depending on the condition and its severity.
  • the compounds taught herein are administered alone or in combination with cytokines IL-6 or IFNa to trea a patient with a proliferative disease.
  • proliferative disease refers to a cancer, (and/or any metastases) or hyperproiiferative condition, such as a leukemia, lymphoma or multiple myeloma.
  • the term also includes benign tumors, malignant tumors, rheumatoid arthritis, psoriasis, ocular angiogenesis diseases, Osier-Webber Syndrome, myocardial angiogenesis, plaque neovascularization, graft and post-angioplasty stenosis, telani ectasia, hemophiliac joints, angiofibroma, wound granulation, intestinal adhesions, atherosclerosis, scleroderma, hypertrophic scars, cat scratch disease, and Heliobacter pylori ulcers or metastasis.
  • the multiple therapeutic agents may be administered in any order or even simultaneously, if simultaneously, the multiple therapeutic agents may be provided in a single, unified form, or in multiple forms (by way of example only, either as a single pill or as two separate pills).
  • One of the therapeutic agents may be given in multiple doses, or both may be given as multiple doses. If not simultaneous, the timing between the multiple doses may be any duration of time ranging from a few minutes to four weeks.
  • the present invention provides methods for treating
  • STAT3-mediated disorders in a human or animal subject in need of such treatment comprising administering to said subject an amount of a compound of the present invention effective to reduce or prevent said disorder in the subject in combination with at least one additional agent for the treatment of said disorder that is known in the art.
  • the present invention provides therapeutic compositions comprising at least one compound of the present invention in combination with one or more additional agents for the treatment of STAT3.
  • the compounds of the subject invention may be useful for the treatment or disorders of a wide variety of condition where inhibition or modulation of STAT3 is useful.
  • Disorders or conditions advantageously treated by the compounds of the subject invention include the prevention or treatment of cancer, such as colorectal cancer, and cancer of the breast, lung, prostate, bladder, cervix and skin.
  • neoplasias including but not limited to brain cancer, bone cancer, a leukemia, a lymphoma, epithelial cell-derived neoplasia (epithelial carcinoma) such as basal cell carcinoma, adenocarcinoma, gastrointestinal cancer such as lip cancer, mouth cancer, esophogeal cancer, small bowel cancer and stomach cancer, colon cancer, liver cancer, bladder cancer, pancreas cancer, ovary cancer, cervical cancer, lung cancer, breast cancer and skin cancer, such as squamous cell and basal cell cancers, prostate cancer, renal cell carcinoma, and other known cancers that effect epithelial cells throughout the body.
  • epithelial cell-derived neoplasia epithelial carcinoma
  • basal cell carcinoma such as basal cell carcinoma, adenocarcinoma
  • gastrointestinal cancer such as lip cancer, mouth cancer, esophogeal cancer, small bowel cancer and stomach cancer
  • colon cancer liver cancer, bladder cancer, pancreas cancer
  • the neoplasia can be selected from gastrointestinal cancer, liver cancer, bladder cancer, pancreas cancer, ovary cancer, prostate cancer, cervical cancer, lung cancer, breast cancer and skin cancer, such as squamous ceil and basal cell cancers.
  • the compounds and formulations of the present invention are also useful for veterinary treatment of companion animals, exotic animals and farm animals, including mammals, rodents, and the like. More preferred animals include horses, dogs, and cats.
  • Examples 1 to 8 can be synthesized using the following general and exemplary synthetic procedure:
  • HBr / AcOH solution (3.5 rnmol) was added to the solution of penta-O-acetyl-D-mannose (1) (1 mmol) in mixture of AcOH and Ac 2 0 (1 : 1, v/v) (4 mL). The reaction mixture was stirred at room temperature until reaction was completed (TLC control). Then the reaction mixture was diluted with dichloromethane (40 mL) and washed with sat.NaCOs aqueous solution and subsequently with water until neutral. The organic layer was dried over Na 2 S0 4 .
  • Figure 9 the effects of 1 ⁇ auranoftn in combination with 10 IU/ml IFNa or 20 ng/ml IL-6 on the proliferation of CTCL HH in normoxia or hypoxia condition for 72 hours.
  • 30,000 cells/well of CTCL HH were plated in each well of a 96-well plate containing 100 ⁇ of RPMI with 10% FBS and 1% pen/strep at 37°C and 5% C0 2 .
  • the ceils were treated with 1 ⁇ auranofin, 10 lU/ml IFNa, 20 ng/ml IL-6, 1 ⁇ auranofin and 10 l U/ml IFNa, or 20 ng/ml IL-6 and 1 ⁇ auranofin for 72 hours.
  • Promega's MTS reagent were added to the cells according to manufacturer's instructions and incubated for 1.5 hours. The plates were read at 490 nm and the resulting data graphed with GraphPad Prism 5 software.
  • FIG. 10 shows the results of treating CTL HH, Hut78, and MJ cells with different concentrations of the compound of Example I and after being incubated for 72 hours.
  • 60,000 cells/well of CTCL HH, 30,000 cells/ well of HuT78, and 30,000 cells/well of MJ were plated in each well of a 96- well plate containing 100 ⁇ of RPMI with 10% FBS and 1% pen/strep and allowed to grow for 24 hours at 37°C 5% C(3 ⁇ 4.
  • the cells were treated with different concentrations of drugs and incubated for 72 hours.
  • Promega's MTS reagent were added to the cells according to manufacturer's instructions and incubated for 1.5 hours.
  • the plates were read at 490 nm and the resulting data graphed with GraphPad Prism 5 software,
  • Figure 1 1 shows the effects of Auranofin, WP1531 , WP1533 on pSTAT3 expression in BT-58 for 4 h with 5 IU/ml of IFNa stimulation for 30 min in 10% serum.
  • 500,000 cells of BT-58 were seeded in 2 ml of DMEM/F12 supplemented 10 ng/ml of EGF and bFGF and 10% FBS. Cells were allowed to grow for 16 h then treated with 0.8, 1.5, 3 ⁇ of Auranofin and 0.4, 0.8, and 1.5 ⁇ of WP1531, and WP 1533 for 4h. Cells were then stimulated with 5 IU/ml of IFNa for 30 min. Lysates were collected and protein concentration was determined. 40 ⁇ g were ran out on each lane on MSD plate detecting pSTAT3.
  • Figure 12 shows the effects of Auranofin, WP1531, and WP1533 on the proliferation of BT-58 and 58-10F for 72 h (MTS).
  • MTS 72 h
  • 4,000 cells/well of BT-58, and 58-10F were seeded in each w r ell of a 96-well plate containing 100 ⁇ of DMEM/F12 media.
  • the cells were then treated with different concentrations of drugs and incubated for 72 h at 37° C in 5% C0 2 .
  • Promega's MTS reagent were added to the cells according to ma ufacture's instructions and incubated for 1.5 h.
  • the plates were read at 490 nm and resulting data graphed with GraphPad Prism 5 software.
  • Figure 13 shows the effects of WP1547 on the proliferation of BT-58, 58-10F
  • 99 BT-58, 58-1 OF, U87, and WM35 respectively were plated in each well of a 96 well plate containing 100 ⁇ media appropriate to each cell line.
  • the cells were allowed to grow for 24 hr at 37° C in 5% C0 2 .
  • the cells were then treated with different concentration of drugs and incubated for 72 hr
  • Promega's MTS reagent were added to the cells according to manufacture's instructions and incubated for 1.5 hr
  • the plate were read at 490 nm and resulting data graphed with GraphPad Prism 5 software.
  • Figure 14 shows the effects of WP1546 on the proliferation of BT-58, 58-10F
  • U87, and WM35 for 72h (MTS). Specifically, 5,000, 4000, 10000, 7000 cells per well of BT- 58, 58-10F, U87, and WM35 respectively were plated in each well of a 96 well plate containing 100 ⁇ media appropriate to each cell line. The ceils were allowed to grow for 24 hr at 37° C in 5% C0 . The cells were then treated with different concentration of drugs and incubated for 72 hr Promega's MTS reagent were added to the cells according to manufacture's instructions and incubated for 1.5 hr The plate were read at 490 nm and resulting data graphed with GraphPad Prism 5 software.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des analogues d'auranofine et des compositions pharmaceutiques qui inhibent le p-STAT3, conjointement avec des procédés de synthèse et des procédés d'utilisation des composés. L'invention concerne également des procédés de traitement de maladies et de troubles de p-STAT3 chez un patient en ayant besoin par administration d'une quantité thérapeutiquement efficace d'un ou plusieurs de ces composés, seuls ou en combinaison avec une autre thérapie médicamenteuse. Les composés et compositions pharmaceutiques selon l'invention sont utiles pour traiter des maladies prolifératives et troubles prolifératifs comprenant, mais sans y être limités, le cancer.
PCT/US2012/033837 2011-04-14 2012-04-16 Auranofine et analogues d'auranofine utiles pour traiter une maladie proliférative et des troubles prolifératifs Ceased WO2012142615A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161475600P 2011-04-14 2011-04-14
US61/475,600 2011-04-14

Publications (2)

Publication Number Publication Date
WO2012142615A2 true WO2012142615A2 (fr) 2012-10-18
WO2012142615A3 WO2012142615A3 (fr) 2013-01-31

Family

ID=47010040

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/033837 Ceased WO2012142615A2 (fr) 2011-04-14 2012-04-16 Auranofine et analogues d'auranofine utiles pour traiter une maladie proliférative et des troubles prolifératifs

Country Status (1)

Country Link
WO (1) WO2012142615A2 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103980330A (zh) * 2014-04-04 2014-08-13 济南圣泉唐和唐生物科技有限公司 一种异硫脲氢溴酸盐的制备方法
US8927506B2 (en) 2008-07-11 2015-01-06 Board Of Regents, The University Of Texas System Acetates of 2-deoxy monosaccharides with anticancer activity
WO2015127234A1 (fr) * 2014-02-20 2015-08-27 Board Of Regents, The University Of Texas System Utilisation d'ibrutinib pour le traitement du cancer à mutation de l'egfr
CN107043404A (zh) * 2016-11-24 2017-08-15 中山大学肿瘤防治中心 新型膦金配合物及其抗肿瘤应用
US10201554B2 (en) 2013-04-05 2019-02-12 Board Of Regents, The University Of Texas System Esters of 2-deoxy-monosacharides with anti proliferative activity
CN112206238A (zh) * 2019-07-09 2021-01-12 厦门大学 金诺芬在肺癌治疗中的应用
JP2021017451A (ja) * 2019-07-23 2021-02-15 合同会社エルム労働衛生科学 金錯体を含む抗癌剤及び化学放射線療法における放射線との併用剤
WO2021185773A1 (fr) 2020-03-16 2021-09-23 Produkem Molekulares Design Gmbh Agents contenant de l'or pour le traitement d'infections pulmonaires
US11485750B1 (en) 2019-04-05 2022-11-01 Kymera Therapeutics, Inc. STAT degraders and uses thereof
WO2023242100A1 (fr) 2022-06-13 2023-12-21 KHR Biotec GmbH Nouveaux inhibiteurs de ras

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670330B1 (en) * 2000-05-01 2003-12-30 Theodore J. Lampidis Cancer chemotherapy with 2-deoxy-D-glucose
WO2003018598A2 (fr) * 2001-08-30 2003-03-06 University College Dublin Derives de monosaccharides
US20050143336A1 (en) * 2003-12-30 2005-06-30 Board Of Regents, The University Of Texas System Methods and compositions for improved non-viral gene therapy
BRPI0708273A2 (pt) * 2006-02-24 2011-05-24 Univ Texas uso de compostos de hexoses
US9149489B2 (en) * 2006-04-27 2015-10-06 Board Of Regents, University Of Texas System Inhibitors of glycolysis useful in the treatment of brain tumors
ES2628180T3 (es) * 2008-07-11 2017-08-02 Board Of Regents, The University Of Texas System Nuevos acetatos de 2-desoxi monosacáridos con actividad anticancerosa

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8927506B2 (en) 2008-07-11 2015-01-06 Board Of Regents, The University Of Texas System Acetates of 2-deoxy monosaccharides with anticancer activity
US10201554B2 (en) 2013-04-05 2019-02-12 Board Of Regents, The University Of Texas System Esters of 2-deoxy-monosacharides with anti proliferative activity
US11925654B2 (en) 2013-04-05 2024-03-12 Board Of Regents, The University Of Texas System Esters of 2-deoxy-monosaccharides with anti proliferative activity
US11026960B2 (en) 2013-04-05 2021-06-08 Board Of Regents, The University Of Texas System Esters of 2-deoxy-monosaccharides with anti proliferative activity
WO2015127234A1 (fr) * 2014-02-20 2015-08-27 Board Of Regents, The University Of Texas System Utilisation d'ibrutinib pour le traitement du cancer à mutation de l'egfr
CN103980330B (zh) * 2014-04-04 2017-02-01 济南圣泉唐和唐生物科技有限公司 一种异硫脲氢溴酸盐的制备方法
CN103980330A (zh) * 2014-04-04 2014-08-13 济南圣泉唐和唐生物科技有限公司 一种异硫脲氢溴酸盐的制备方法
CN107043404B (zh) * 2016-11-24 2020-08-11 中山大学肿瘤防治中心 新型膦金配合物及其抗肿瘤应用
CN107043404A (zh) * 2016-11-24 2017-08-15 中山大学肿瘤防治中心 新型膦金配合物及其抗肿瘤应用
US11485750B1 (en) 2019-04-05 2022-11-01 Kymera Therapeutics, Inc. STAT degraders and uses thereof
US12077555B2 (en) 2019-04-05 2024-09-03 Kymera Therapeutics, Inc. STAT degraders and uses thereof
US11746120B2 (en) 2019-04-05 2023-09-05 Kymera Therapeutics, Inc. Stat degraders and uses thereof
CN112206238A (zh) * 2019-07-09 2021-01-12 厦门大学 金诺芬在肺癌治疗中的应用
JP2021017451A (ja) * 2019-07-23 2021-02-15 合同会社エルム労働衛生科学 金錯体を含む抗癌剤及び化学放射線療法における放射線との併用剤
JP7683177B2 (ja) 2019-07-23 2025-05-27 合同会社エルム労働衛生科学 金錯体を含む抗癌剤及び化学放射線療法における放射線との併用剤
WO2021185773A1 (fr) 2020-03-16 2021-09-23 Produkem Molekulares Design Gmbh Agents contenant de l'or pour le traitement d'infections pulmonaires
AT523662B1 (de) * 2020-03-16 2023-07-15 Aurovir Pharma Gmbh Gold-haltige Mittel zur Behandlung von Lungeninfektionen
AT523662A1 (de) * 2020-03-16 2021-10-15 Produkem Molekulares Design Gmbh Gold-haltige Mittel zur Behandlung von Lungeninfektionen
US12569515B2 (en) 2020-03-16 2026-03-10 Aurovir Pharma Gmbh Gold-containing agents for the treatment of lung infections
WO2023242100A1 (fr) 2022-06-13 2023-12-21 KHR Biotec GmbH Nouveaux inhibiteurs de ras

Also Published As

Publication number Publication date
WO2012142615A3 (fr) 2013-01-31

Similar Documents

Publication Publication Date Title
WO2012142615A2 (fr) Auranofine et analogues d'auranofine utiles pour traiter une maladie proliférative et des troubles prolifératifs
CN109665968B (zh) 并环化合物及其制备方法和用途
EP3653620B9 (fr) Nouveaux dérivés hétéroarylamide utilisés en tant qu'inhibiteurs sélectifs de l'histone déacétylase 1 et 2 (hdac1/2)
CN114853754B (zh) 一种硫代酰胺衍生物及其制备方法和应用
KR100602977B1 (ko) 안트라닐산 아미드 및 ｖｅｇｆ 수용체 티로신 키나제억제제로서 그의 용도
CN110461836B (zh) 一种选择性抑制激酶化合物及其用途
TW202313559A (zh) 組蛋白去乙醯化酶6和熱休克蛋白90之雙重抑制劑
KR102767745B1 (ko) 신규 아미드계 화합물, 및 이것을 사용한 Pin1 저해제, 염증성 질환의 치료제 및 암의 치료제
JP2016539956A (ja) ゲムシタビン誘導体、該誘導体を含む組成物及び該誘導体の製薬用途
CN107501279B (zh) 呋喃并喹啉二酮类化合物及其医药用途
HRP20020103A2 (en) Heterocyclic compounds inhibiting angiogenesis
US9399644B2 (en) [1,3] dioxolo [4,5-G] quinoline-6(5H)thione derivatives as inhibitors of the late SV40 factor (LSF) for use in treating cancer
CN111848572B (zh) 酰胺类化合物及其制备方法和用途
US20240124515A1 (en) Orally active leukemia inhibitory factor (lif) antagonists for the treatment of cancer
JP2025515036A (ja) ＰＩＫｆｙｖｅキナーゼ阻害剤
EP4442684A1 (fr) Classe de composés de pyrimidine, son procédé de préparation et son utilisation
EP3849550B1 (fr) Polythérapie pour le traitement du cancer du sein positif au récepteur des oestrogènes
CN111171041B (zh) 20位取代的喜树碱衍生物及其制备方法和应用
CN113880845A (zh) 吡咯并三嗪衍生物及其制备方法和应用
KR20210151849A (ko) 퀴놀린 유도체 및 암의 치료를 위한 그의 용도
US7799811B2 (en) Agent for prevention and treatment of cancer comprising oxadiazole urea compound obstructing activity of stat
CN107556315B (zh) 含四元环的咪唑衍生物
CN105745187B (zh) 用于治疗肿瘤性疾病的化合物
KR102532517B1 (ko) 신규한 설폰아미드 화합물 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약제학적 조성물
CN108864074A (zh) 一种化合物及其作为选择性pi3k抑制剂在治疗肿瘤中的应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12771343

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12771343

Country of ref document: EP

Kind code of ref document: A2